Invesaro

Stocks Comparison

AbbVie vs Bristol Myers Squibb: revenue, profit, margins and growth compared

AbbVie brought in $61.2B of revenue in fiscal 2025, Bristol Myers Squibb $48.2B in fiscal 2025. Revenue changed by +8.6% at AbbVie and -0.2% at Bristol Myers Squibb on the year before, so AbbVie grew faster. AbbVie kept 6.9% of its revenue as net profit, Bristol Myers Squibb 14.6%. Free cash flow was $17.8B at AbbVie and $12.8B at Bristol Myers Squibb.

Side by side, latest fiscal year

ABBVBMY
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$61.2B$48.2B
Revenue growth+8.6%-0.2%
Net income$4.2B$7.1B
Net margin6.9%14.6%
Free cash flow$17.8B$12.8B
Free cash flow margin29.1%26.7%
Earnings per share (diluted)$2.36$3.46
Cash$5.2B$10.2B
Debt$64.5B$44.8B
Price to earnings112.018.2
Market value$467.1B$128.4B
Dividend yield2.52%3.96%
Rank by revenue in sector#14 of 523 · Health care#16 of 523 · Health care

Over the years

Revenue
ABBV FY2018: $32.8BABBV FY2019: $33.3BABBV FY2020: $45.8BABBV FY2021: $56.2BABBV FY2022: $58.1BABBV FY2023: $54.3BABBV FY2024: $56.3BABBV FY2025: $61.2BBMY FY2018: $22.6BBMY FY2019: $26.1BBMY FY2020: $42.5BBMY FY2021: $46.4BBMY FY2022: $46.2BBMY FY2023: $45BBMY FY2024: $48.3BBMY FY2025: $48.2BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $61.2BBMY $48.2B
Net income
ABBV FY2018: $5.7BABBV FY2019: $7.9BABBV FY2020: $4.6BABBV FY2021: $11.5BABBV FY2022: $11.8BABBV FY2023: $4.9BABBV FY2024: $4.3BABBV FY2025: $4.2BBMY FY2018: $4.9BBMY FY2019: $3.4BBMY FY2020: -$9BBMY FY2021: $7BBMY FY2022: $6.3BBMY FY2023: $8BBMY FY2024: -$8.9BBMY FY2025: $7.1BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $4.2BBMY $7.1B
Net margin
ABBV FY2018: 17.4%ABBV FY2019: 23.7%ABBV FY2020: 10.1%ABBV FY2021: 20.5%ABBV FY2022: 20.4%ABBV FY2023: 9.0%ABBV FY2024: 7.6%ABBV FY2025: 6.9%BMY FY2018: 21.8%BMY FY2019: 13.2%BMY FY2020: -21.2%BMY FY2021: 15.1%BMY FY2022: 13.7%BMY FY2023: 17.8%BMY FY2024: -18.5%BMY FY2025: 14.6%FY18FY19FY20FY21FY22FY23FY24FY25
ABBV 6.9%BMY 14.6%
Revenue growth
ABBV FY2019: +1.6%ABBV FY2020: +37.7%ABBV FY2021: +22.7%ABBV FY2022: +3.3%ABBV FY2023: -6.4%ABBV FY2024: +3.7%ABBV FY2025: +8.6%BMY FY2019: +15.9%BMY FY2020: +62.6%BMY FY2021: +9.1%BMY FY2022: -0.5%BMY FY2023: -2.5%BMY FY2024: +7.3%BMY FY2025: -0.2%FY19FY20FY21FY22FY23FY24FY25
ABBV +8.6%BMY -0.2%
Free cash flow
ABBV FY2018: $12.8BABBV FY2019: $12.8BABBV FY2020: $16.8BABBV FY2021: $22BABBV FY2022: $24.2BABBV FY2023: $22.1BABBV FY2024: $17.8BABBV FY2025: $17.8BBMY FY2018: $6.1BBMY FY2019: $7.4BBMY FY2020: $13.3BBMY FY2021: $15.2BBMY FY2022: $11.9BBMY FY2023: $12.7BBMY FY2024: $13.9BBMY FY2025: $12.8BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $17.8BBMY $12.8B

Fiscal years as each company reports them; the two may end in different months.

Questions about AbbVie and Bristol Myers Squibb

Which is bigger by revenue, AbbVie or Bristol Myers Squibb?

AbbVie is bigger by revenue: $61.2B in fiscal 2025, against $48.2B for Bristol Myers Squibb in fiscal 2025.

Which keeps more of its revenue as profit, AbbVie or Bristol Myers Squibb?

AbbVie had a net margin of 6.9% in fiscal 2025; Bristol Myers Squibb had 14.6% in fiscal 2025.

Which grew revenue faster, AbbVie or Bristol Myers Squibb?

In their latest fiscal years revenue changed by +8.6% at AbbVie and -0.2% at Bristol Myers Squibb.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies